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INTRODUCTION:  Ameloblastomas  are  rare  head  and  neck tumors,  and  yet  the  most  common  odontogenic
neoplasms.  They  account  for 1% and  11%  of  all head  and  neck  and  odontogenic  tumors  respectively.
Embryologically,  they  originate  from  remnants  of  odontogenic  epithelium.  Their aggressive,  destructive
nature,  as well  as  their  anticipated  high  rate  of recurrence,  even  after  en  bloc  resection,  poses  a  surgical
predicament.
PRESENTATION:  We  present  a case  of a 56  year-old  Asian  female  with  a multi-recurrent  invasive
ameloblastoma.  Initially,  the lesion  was mandibular  in  location  for which  she  underwent  a mandiblec-
tomy.  Later  on,  she  presented  with  a maxillary  ameloblastoma  with  invasion  of both  the  anterior  wall
of  the maxillary  sinus  and  the ﬂoor  of the  orbit.  The  patient  was  operated  twice  and  histopathol-
ogy conﬁrmed  a cystic  type  recurrent  ameloblastoma.  A year  later,  she  came  with  recurrent  maxillary
ameloblastoma  and  a maxillectomy  was  done.  However,  histopathology  revealed  a follicular  ameloblas-
toma.  Three  years  later,  she  presented  with  a retro-orbital  ameloblastoma  with  inﬁltration  to the  temporal
muscles.  The  patient  was  operated  and  the  histopathologic  examination  revealed  a  partially  cystic  lesion
with no  malignant  transformation.
CONCLUSION:  This  case  discusses  available  treatment  options  and  emphasizes  on  the importance  of  long-
ue  to 
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. Introduction
Ameloblastomas are common odontogenic tumors that arise
rom the dental epithelium. Proposed etiologies by Smith J.F. is that
hey arise from the dental lamina or basal cells of the oral epithe-
ium, or from cells that differentiated to mimic  the ameloblast [1].
wing to modern radiology, the early detection and monitoring
f such invasive tumors are now readily possible, acknowledging
heir tendencies for recurrence and malignant transformation.
In the current report we present a multi-recurrent case of
meloblastoma discussing the potential causes of the recurrence
nd available treatment options, recognizing the rarity of reported
ases in the literature and lack of unanimous treatment guidelines.
. Presentation of case
A ﬁfty-six year-old Asian female, known case of multi-recurrent
meloblastoma, with a long history of multiple surgeries reported
o the department of plastic and reconstructive surgery of Henri
ondor Hospital, Paris.
∗ Corresponding author. Present address: 7 Rue Ginette Watelle, 21000 Dijon,
rance.
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ttp://dx.doi.org/10.1016/j.ijscr.2016.11.039
210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing G
reativecommons.org/licenses/by-nc-nd/4.0/).the  biological  behavior  of  ameloblastoma.
shed  by  Elsevier  Ltd  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
 BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Back in 1986, she has been referred by her dentist upon ﬁnd-
ing a suspicious lesion on her panoramic radiograph and with a
chief complaint of a non-tender swelling in that region to the Pitié-
Salpêtrière Hospital where she underwent a hemimandibulectomy,
as the ﬁrst surgical intervention.
Her second presentation was in 2005 for the same reason, for
which she underwent her second surgical procedure in a different
hospital. However sufﬁcient data concerning this presentation was
lacking.
In 2009, the patient was referred to our department for the ﬁrst
time with a diagnosis of recurrent left maxillary ameloblastoma
with orbital invasion, associated with lytic bony lesions of the zygo-
matic arch, the anterior wall of the maxillary sinus and the ﬂoor of
the orbit. She underwent resection of the tumor that was attached
to the orbital fat and anterior wall of the maxillary sinus. The orbital
ﬂoor was reconstructed using Resorbix. Histopathological exami-
nation revealed a unicystic ameloblastoma with positive surgical
margins, and the left infra-orbital nerve was of normal hitology.
A follow-up MRI  done 3 weeks post-operatively demonstrating an
almost complete resection of the left maxillary lesion and persis-
tence of small incidental tissues in the posteromedial wall of the left
infra-temporal fossa. A repeated MRI  conﬁrmed the progression of
the disease, and accordingly she was  scheduled for another surgi-
cal intervention. Histopathologic examinations corresponded with
a follicular type ameloblastoma. The lesion was formed by islands
roup Ltd. This is an open access article under the CC BY-NC-ND license (http://
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dig. 1. Resection of recurrent ameloblastoma of the left anterior wall of the maxillary
inus, the zygomatic arch, and of the ﬂoor of the orbit.
f odontogenic epithelium, limited by a palisading border with
everse polarization. Although surgical margins were negative, they
ere only located 1 mm from the lesion. All the subsequent follow-
p imaging modalities substantiated a complete surgical resection
f the tumor, with no evidence of recurrence.
In 2015, the patient’s MRI  demonstrated a heterogeneous mass
osterior to the left eye, pushing the left medial rectus muscle,
uggestive of either a recurrent or a progressive disease. Fur-
hermore, 2 suspicious enlarged nodularities were seen on lower
evels. No meningeal invasion could be identiﬁed. A CT facial bone
evealed a homogeneous nodular tissue formation on the exter-
al wall of the left eye measuring 32 mm in the largest diameter,
ushing against the greater wing of the sphenoid bone with no
djacent bone remodeling. Accordingly, the patient underwent an
xcision of the left retro-orbital ameloblastoma (Figs. 1 and 2).
sing Hematoxylin-Eosin-Saffaron stains, the histopathology cor-
oborated the diagnosis of a recurrent cystic ameloblastoma with
ositive surgical margins. The tumor was formed by massive
asophilic cells inﬁltrating the center. The post-operative period
as uneventful and her succeeding follow-ups conﬁrmed no evi-
ence of recurrence or malignant transformation.
. Discussion
Ameloblastomas are histologically benign, locally invasive
dontogenic tumors. Accounting for 1% of all head and neck tumors,
nd 11% of odontogenic tumors, they are considered the second
ost common odontogenic tumors after odontomas. They were
rst recognized by Cusack in 1827, and named in 1930 by Ivy
nd Churchill [2]. They are histopathologically divided into 6 sub-
ypes: follicular, plexiform, acanthomatous, basal, unicystic and
esmoplastic ameloblastomas. Mixed pathological patterns are notFig. 2. Ameloblastoma with 1 mm of margins.
uncommon, and the lesion is usually classiﬁed according to the
predominant type.
Amelobastomas are more common in adults than in children,
with the average age being 20–40 years [2]. They have no sex or
race proclivity, although some reports allege an increased rate in
the Asian and black population [2].
Ameloblastomas arise more frequently in the mandible 80%,
especially in the area of the molar and the ascending ramus, and
in the maxilla 20% [3].
Due to their aggressive behavior, several interventions have
been proposed in the literature to prevent their local recurrence,
invasion to adjacent structures and transformation to malignancy.
Ameloblastomas are managed conservatively by enucleation
with bone curettage, or radically by surgery with segmental or
marginal resection. Many surgeons advocate margins of 1.5 cm of
clinically normal bone. Additionally, the use of radiotherapy is con-
troversial. Most clinicians ﬁnd no place for radiotherapy in treating
ameloblastomas, considering them radioresistant. This belief was
supported by literature published in premegavoltage days of radi-
ation therapy [4]. Advancement in radiotherapy resulted in cases
of ameloblastoma responding to them, and respectively, several
articles reported their success [4–7].
The pathogenesis of ameloblastoma had not been clear until
recently when research groups published their results postulating
the genes involved [8–10]. The BRAF protein in the mitogen-
activated protein kinase pathway (MAPK) has been commonly
found to be mutated, rendering the pathway constitutively active
[9]. This is also the most common activating mutation found in can-
cers such as colorectal, thyroid and melanoma [11]. Another gene
discovered to play a role in ameloblastoma is the hedgehog path-
way gene, however it is less commonly found than MAPK [8,10].
Several target therapies to mutated genes are currently in clinical
trial, and some have shown to inhibit some pathways in vitro or vivo
[8,12]. Therefore, since MAPK is the commonest pathway involved,
it should be carefully studied as a target therapy for ameloblastoma.
Concerning the presented case, due to the proximity of the
lesion to vital structure and the level of local invasion, sufﬁcient
margins were not conceivably achieved. With reported recurrence
rates ranging as high as 92% with conservative treatment [13], and
14–25% with radial approach [14], we  opted for monitoring the
patient clinically with regular follow-ups and CT scans. However,
deliberating the risk of malignant transformation, the addition of
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n adjuvant radio-therapeutic treatment is possible in case local
ontrol could not be obtained.
A recent WHO  classiﬁcation, distinguished between ameloblas-
oma and malignant ameloblastoma [15]. Malignant ameloblas-
oma was further categorized into two types: metastasizing
meloblastoma and ameloblastic carcinoma (AC). Metastasizing
meloblastoma was deﬁned as benign ameloblastoma histolog-
cally with metastatic spread to distant sites, while the latter
emonstrated malignant histology and furthermore subdivided
nto: primary and secondary types. Primary AC arises de novo, while
econdary AC result from malignant transformation of a primary
esion after repeated postsurgical recurrences [16].
. Conclusion
This case presents our experience with a multi-recurrent unicys-
ic ameloblastoma that until present revealed no signs of malignant
ransformation, yet poses a surgical predicament. In this report
e aim to support the critical signiﬁcance of regular follow-ups of
atients with ameloblastoma, in an attempt to minimize the risks
f local recurrence and malignant transformation.
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